Analyst Reco. Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Real-time Estimate Cboe BZX Other stock markets 11:47:02 2024-04-29 am EDT			5-day change	1st Jan Change
93.86 ^USD	+0.93%		+3.39%	+1.56%

Apr. 25	Transcript : Blueprint Medicines Corporation - Special Call
Mar. 22	Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	Feb. 15	MT
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	Feb. 13	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	Jan. 31	MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating	Jan. 09	MT
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating	Jan. 08	MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating	Dec. 22	MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating	Dec. 19	MT
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating	Dec. 11	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating	23-10-27	MT
Barclays Raises Price Target on Blueprint Medicines to $58 From $46, Maintains Equalweight Rating	23-10-27	MT
Needham Raises Blueprint Medicines Price Target to $74 From $66, Maintains Buy Rating	23-10-27	MT
Oppenheimer Upgrades Blueprint Medicines to Outperform From Perform, $85 Price Target	23-10-27	MT
Wedbush Raises Blueprint Medicines' Price Target to $80 From $75 After Higher-Than-Expected Q3 Financial Results, Keeps Outperform Rating	23-10-26	MT
Needham Adjusts Price Target on Blueprint Medicines to $66 From $65, Maintains Buy Rating	23-08-21	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $83 From $93, Maintains Buy Rating	23-08-03	MT
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $59 From $55, Maintains Equal-Weight Rating	23-08-03	MT
Wells Fargo Upgrades Blueprint Medicines to Overweight From Equalweight, Adjusts Price Target to $82 From $55	23-07-31	MT
Wells Fargo Raises Price Target on Blueprint Medicines to $55 From $48, Maintains Equal-Weight Rating	23-06-14	MT
SVB Securities Downgrades Blueprint Medicines to Underperform From Market Perform, Cuts Price Target to $43 From $48	23-06-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Analyst Reco.

Filters